Donor-derived γδ T cell therapy for MRD-positive AML after stem-cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, randomized, open-label Early Phase I trial gives ex-vivo expanded allogeneic γδ T cells to adults with MRD-positive AML following allo-HSCT. Participants are randomized to one of two infusion dose levels (2E8 cells/kg or 4E8 cells/kg) and are closely monitored for safety and changes in MRD. Eligible patients are adults classified as favorable-to-intermediate risk by 2022 ELN who are MRD-positive by flow cytometry or PCR, have inactive GVHD, ECOG 0–2, and adequate marrow and organ function. The trial’s primary focus is early safety and signals of anti-leukemia activity to guide future larger studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients should sign informed consent form voluntarily before the trail and comply with the requirements of this study.
2. Age≥18 years old, gender unlimited.
3. All the subjects met the 2016 WHO classification and were diagnosed with AML via MICM (Morphology,Immunophenotyping, Cytogenetics, and Molecular genetics).
4. AML patients receiving allo-HSCT.
5. Subjects classified into the favorable -to-intermediate risk group according to the 2022 European Leukemia Net (ELN) risk stratification guidelines.
6. All subjects were detected positive for MRD, and MRD was positive by flow cytometry (MFC) or/and positive for fusion genes/gene mutations by RQ-PCR.
7. ECOG performance status score: 0-2.
8. Inactive GVHD (acute GVHD grade II-IV or moderate to severe chronic GVHD).
9. Adequate bone marrow reserve, defined as: absolute neutrophil count (ANC) \> 0.5E9/L and platelet count ≥20E9/L.
10. Adequate organ function as per protocol.
11. Male and female patients of reproductive potential must agree to use birth control during the study and for at least 28 days post study.

Exclusion Criteria:

1. Post-transplant relapse or extramedullary disease: AML patients post-allo-HSCT with ≥5% blasts in peripheral blood or bone marrow (excluding causes such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia infiltration.
2. Active GVHD: Subjects with active GVHD within 30 days before screening.
3. Active infections: HBV, HCV, HIV, syphilis (TP), active CMV, or EBV infection.
4. Neurological disorders: active autoimmune or inflammatory neurological diseases, clinically significant active cerebrovascular disease.
5. Unstable systemic diseases, including: unstable angina, cerebrovascular accident or transient ischemic attack (within 6 months before screening), myocardial infarction (within 6 months before screening), NYHA Class III/IV heart failure, refractory hypertension (defined as failure to control blood pressure despite lifestyle modifications and treatment with ≥4 antihypertensive drugs, including diuretics, for \>1 month), clinically significant arrhythmias requiring medication, severe hepatic, renal, or metabolic disorders.
6. Major surgery: Subjects who underwent major surgery within 4 weeks before screening, as deemed ineligible by the investigator.
7. Concurrent non-hematologic malignancies.
8. Cardiac abnormalities, meeting any of the following: Left ventricular ejection fraction (LVEF) ≤45%. NYHA Class III/IV congestive heart failure. QTc interval \>480 msec. Other cardiac conditions considered unsuitable by the investigator.
9. History of epilepsy or other active CNS disorders.
10. Uncontrolled infections: active systemic infections requiring treatment (e.g., sepsis, bacteremia, fungemia, tuberculosis, opportunistic infections).
11. Recent participation in other interventional trials: Subjects who participated in another interventional clinical study within 30 days prior to enrollment.
12. Other conditions: Any other circumstances deemed by the investigator to compromise subject safety or trial integrity.

Where it's running

• Institute of Hematology & Blood Diseases Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Erlie Jiang, M.D.;Ph.D
• Email: jiangerlie@ihcams.ac.cn
• Phone: 022-23909180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Allogeneic CAR-T CT0890B for relapsed/refractory AML

  This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.

  Recruiting Phase 1 Peking University People's Hospital · Beijing · NCT07617285

• Biomarkers in Bone Marrow to Predict AML Chemosensitivity

  This study tests whether markers in bone marrow can predict how adults with AML will respond to chemotherapy.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07587944

• Azacitidine plus venetoclax maintenance vs azacitidine alone in AML

  This trial tests whether adding venetoclax to azacitidine maintenance helps people with AML stay disease-free after achieving first remission.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07539818

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.